Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development

Xilis and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to deploy Xilis’s proprietary MicroOrganoSphere™ technology in support of pre-clinical research to accelerate the development of novel cancer therapies.